Abstract
Rats were trained in a two-lever food-reinforced procedure to discriminate between the effects of saline and the opioid kappa receptor agonist ethylketocyclazocine. After acquisition of this discrimination, generalization tests with opioid peptides such as β-endorphin, α-neoendorphin, dynorphin A and some dynorphin-derived peptides were conducted. The rats dose-dependently generalized the effects of intracerebroventricularly injected ethylketocyclazocine but not β-endorphin, α-neoendorphin, dynorphin A1–8, dynorphin A1–13, D-Cys2-L-Cys5-dynorphin A1–13 or dynorphin A.
D-Cys2-L-Cys5-dynorphin A1–13, in contrast to dynorphin A itself, dose-dependently caused analgesia and catatonia that was reversible with naloxone. Studies into the receptor preference of this derivative, using the technique of “selective tolerance”, revealed that this dynorphin derivative is almost devoid of kappa-receptor activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chavkin C, Goldstein A (1981) Specific receptor for the opioid peptide dynorphin: Structure-activity relationships. Proc Natl Acad Sci USA 78:6543–6547
Chavkin C, James IF, Goldstein A (1982) Dynorphin is a specific endogenous ligand of the κ opioid receptor. Science 215:413–415
Colpaert FC (1978) Discriminative stimulus properties of narcotic analgesic drugs. Pharmacol Biochem Behav 9:863–887
Corbett AD, Paterson SJ, McKnight AT, Magnan J, Kosterlitz HW (1982) Dynorphin1–8 and dynorphin1–9 are ligands for the κ-subtype of opiate receptor. Nature 299:79–81
Goldstein A, Chazarossian VE (1980) Immunoreactive dynorphin in pituitary and brain. Proc Natl Acad Sci USA 77:6207–6210
Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood AL (1979) Dynorphin-(1–13), an extraordinary potent opioid peptide. Proc Natl Acad Sci USA 76:6666–6670
Gramsch Ch, Höllt V, Pasi A, Mehraein P, Herz A (1982) Immunoreactive dynorphin in human brain and pituitary. Brain Res 233:65–74
Han JS, Xie CW (1982) Dynorphin: potent analgesic effect in spinal cord of the rat. Life Sci 31:1781–1784
Herman BH, Leslie F, Goldstein A (1980) Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1–13) and D-Ala2-dynorphin-(1–11) in rats. Life Sci 27:883–892
Höllt V, Haarmann, I, Bovermann K, Jerlicz M, Herz A (1980) Dynorphin-related immunoreactive peptides in rat brain and pituitary. Neurosci Lett 18:149–153
Huidobro-Toro J, Yoshimura K, Lee NM, Loh HH, Way EL (1981) Dynorphin interaction at the κ-opiate site. Eur J Pharmacol 72:265–266
Laschka E, Teschemacher H, Mehraein P, Herz A (1976) Sites and actions of morphine involved in the development of physical dependence. Psychopharmacologia 46:141–147
Laurent S, Schmitt S (1983) Central cardiovascular effects of κ-agonist dynorphin-(1–13) and ethylketocyclazocine in the anesthetized rat. Eur J Pharmacol 96:165–169
Leslie FM, Goldstein A (1982) Degradation of dynorphin-(1–13) by membrane-bound rat brain enzymes. Neuropeptides 2:185–196
McKnight AT, Corbett AD, Kosterlitz HW (1983) Increase in potencies of opioid peptides after peptidase inhibition. Eur J Pharmacol 86:393–402
Morley JE, Levine A (1983) Involvement of dynorphin and the kappa opioid receptor in feeding. Peptides 4:797–800
Oka T, Negishi K, Suda M, Sawa A, Fujino M, Wakimasu M (1982) Evidence that dynorphin-(1–13) acts as an agonist on opioid κ-receptors. Eur J Pharmacol 77:137–141
Pfeiffer A, Pasi A, Mehraein P, Herz A (1981) A subclassification of κ-sites in human brain by use of dynorphin 1–17. Neuropeptides 2:89–97
Przewłocki R, Shearman GT, Herz A (1983) Mixed opioid nonopioid effects of dynorphin and dynorphin related peptides after their intrathecal injection in rats. Neuropeptides 3:233–240
Schiller PW, Eggimann B, Nguyen TM-D (1982) Comparative structure-function studies with analogs of dynorphin-(1–13) and [Leu5]enkephalin. Life Sci 31:1777–1780
Schulz R, Wüster M, Krenss H, Herz A (1980) Selective development of tolerance without dependence in multiple opioid receptors of mouse vas defenrens. Nature 285:242–243
Schulz R, Wüster M, Herz A (1982) Endogenous ligands for κ-opiate receptors. Peptides 3:973–976
Shearman GT, Herz A (1982a) Evidence that the discriminative stimulus properties of fentanyl and ethylketocyclazocine are mediated by an interaction with different opiate receptors (1982) J Pharmacol Exp Ther 221:735–739
Shearman GT, Herz A (1982b) Discriminative stimulus properties of narcotic and non-narcotic drugs in rats trained to discriminative opiate κ-receptor agonists. Psychopharmacology 78:63–66
Shearman GT, Herz A (1982c) D-Ala2, D-Leu5-enkephalin generalizes to a discriminative stimulus produced by fentanyl but not ethylketocyclazocine. Pharmacol Biochem Behav 16:249–252
Tulunay FC, Jen MF, Chang JK, Loh HH, Lee NM (1981) Possible regulatory role of dynorphin on morphine and β-endorphin-induced analgesia. J Pharmacol Exp Ther 219:296–298
Woo SK, Tulunay FC, Loh HH, Lee NM (1983) Effect of dynorphin-(1–13) and related peptides on respiratory rate and morphine-induced respiratory rate depression. Eur J Pharmacol 96:117–122
Wüster M, Schulz R, Herz A (1980) Opiate activity and receptor selectivity of dynorphin1–13 and related peptides. Neurosci Lett 20:79–83
Wüster M, Rubini P, Schulz R (1981) The preference of putative pro-enkephalins for different types of opiate receptors. Life Sci 29:1219–1227
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shearman, G.T., Schulz, R., Schiller, P.W. et al. Generalization tests with intraventricularly applied pro-enkephalin B-derived peptides in rats trained to discriminate the opioid kappa receptor agonist ethylketocyclazocine. Psychopharmacology 85, 440–443 (1985). https://doi.org/10.1007/BF00429661
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00429661